Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.

Dangaj D, Bruand M, Grimm AJ, Ronet C, Barras D, Duttagupta PA, Lanitis E, Duraiswamy J, Tanyi JL, Benencia F, Conejo-Garcia J, Ramay HR, Montone KT, Powell DJ Jr, Gimotty PA, Facciabene A, Jackson DG, Weber JS, Rodig SJ, Hodi SF, Kandalaft LE, Irving M, Zhang L, Foukas P, Rusakiewicz S, Delorenzi M, Coukos G.

Cancer Cell. 2019 Jun 10;35(6):885-900.e10. doi: 10.1016/j.ccell.2019.05.004.

PMID:
31185212
2.

Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer.

Coscia F, Lengyel E, Duraiswamy J, Ashcroft B, Bassani-Sternberg M, Wierer M, Johnson A, Wroblewski K, Montag A, Yamada SD, López-Méndez B, Nilsson J, Mund A, Mann M, Curtis M.

Cell. 2018 Sep 20;175(1):159-170.e16. doi: 10.1016/j.cell.2018.08.065.

3.

Combine and Conquer: Double CTLA-4 and PD-1 Blockade Combined with Whole Tumor Antigen Vaccine Cooperate to Eradicate Tumors.

Homicsko K, Duraiswamy J, Doucey MA, Coukos G.

Cancer Res. 2016 Dec 1;76(23):6765-6767. No abstract available.

4.

Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation.

Leisegang M, Engels B, Schreiber K, Yew PY, Kiyotani K, Idel C, Arina A, Duraiswamy J, Weichselbaum RR, Uckert W, Nakamura Y, Schreiber H.

Clin Cancer Res. 2016 Jun 1;22(11):2734-43. doi: 10.1158/1078-0432.CCR-15-2361. Epub 2015 Dec 14.

5.

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--response.

Duraiswamy J, Freeman GJ, Coukos G.

Cancer Res. 2014 Jan 15;74(2):633-4; discussion 635. doi: 10.1158/0008-5472.CAN-13-2752. Epub 2014 Jan 9. No abstract available.

6.

Replenish the source within: Rescuing tumor-infiltrating lymphocytes by double checkpoint blockade.

Duraiswamy J, Freeman G, Coukos G.

Oncoimmunology. 2013 Oct 1;2(10):e25912. Epub 2013 Aug 2.

7.

Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.

Duraiswamy J, Freeman GJ, Coukos G.

Cancer Res. 2013 Dec 1;73(23):6900-12. doi: 10.1158/0008-5472.CAN-13-1550. Epub 2013 Aug 23.

8.

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G.

Cancer Res. 2013 Jun 15;73(12):3591-603. doi: 10.1158/0008-5472.CAN-12-4100. Epub 2013 Apr 30.

9.

A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis.

Mak PA, Rao SP, Ping Tan M, Lin X, Chyba J, Tay J, Ng SH, Tan BH, Cherian J, Duraiswamy J, Bifani P, Lim V, Lee BH, Ling Ma N, Beer D, Thayalan P, Kuhen K, Chatterjee A, Supek F, Glynne R, Zheng J, Boshoff HI, Barry CE 3rd, Dick T, Pethe K, Camacho LR.

ACS Chem Biol. 2012 Jul 20;7(7):1190-7. doi: 10.1021/cb2004884. Epub 2012 Apr 25.

10.

Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells.

Youngblood B, Oestreich KJ, Ha SJ, Duraiswamy J, Akondy RS, West EE, Wei Z, Lu P, Austin JW, Riley JL, Boss JM, Ahmed R.

Immunity. 2011 Sep 23;35(3):400-12. doi: 10.1016/j.immuni.2011.06.015.

11.

Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults.

Duraiswamy J, Ibegbu CC, Masopust D, Miller JD, Araki K, Doho GH, Tata P, Gupta S, Zilliox MJ, Nakaya HI, Pulendran B, Haining WN, Freeman GJ, Ahmed R.

J Immunol. 2011 Apr 1;186(7):4200-12. doi: 10.4049/jimmunol.1001783. Epub 2011 Mar 7.

12.

Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance.

Kandalaft LE, Motz GT, Duraiswamy J, Coukos G.

Cancer Metastasis Rev. 2011 Mar;30(1):141-51. doi: 10.1007/s10555-011-9289-9. Review.

PMID:
21298574
13.

A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy.

Pethe K, Sequeira PC, Agarwalla S, Rhee K, Kuhen K, Phong WY, Patel V, Beer D, Walker JR, Duraiswamy J, Jiricek J, Keller TH, Chatterjee A, Tan MP, Ujjini M, Rao SP, Camacho L, Bifani P, Mak PA, Ma I, Barnes SW, Chen Z, Plouffe D, Thayalan P, Ng SH, Au M, Lee BH, Tan BH, Ravindran S, Nanjundappa M, Lin X, Goh A, Lakshminarayana SB, Shoen C, Cynamon M, Kreiswirth B, Dartois V, Peters EC, Glynne R, Brenner S, Dick T.

Nat Commun. 2010 Aug 24;1:57. doi: 10.1038/ncomms1060.

14.

Inhibition of dengue virus by an ester prodrug of an adenosine analog.

Chen YL, Yin Z, Lakshminarayana SB, Qing M, Schul W, Duraiswamy J, Kondreddi RR, Goh A, Xu HY, Yip A, Liu B, Weaver M, Dartois V, Keller TH, Shi PY.

Antimicrob Agents Chemother. 2010 Aug;54(8):3255-61. doi: 10.1128/AAC.00397-10. Epub 2010 Jun 1.

15.

Inhibition of dengue virus RNA synthesis by an adenosine nucleoside.

Chen YL, Yin Z, Duraiswamy J, Schul W, Lim CC, Liu B, Xu HY, Qing M, Yip A, Wang G, Chan WL, Tan HP, Lo M, Liung S, Kondreddi RR, Rao R, Gu H, He H, Keller TH, Shi PY.

Antimicrob Agents Chemother. 2010 Jul;54(7):2932-9. doi: 10.1128/AAC.00140-10. Epub 2010 May 10.

16.

Dynamic T cell migration program provides resident memory within intestinal epithelium.

Masopust D, Choo D, Vezys V, Wherry EJ, Duraiswamy J, Akondy R, Wang J, Casey KA, Barber DL, Kawamura KS, Fraser KA, Webby RJ, Brinkmann V, Butcher EC, Newell KA, Ahmed R.

J Exp Med. 2010 Mar 15;207(3):553-64. doi: 10.1084/jem.20090858. Epub 2010 Feb 15.

17.

An adenosine nucleoside inhibitor of dengue virus.

Yin Z, Chen YL, Schul W, Wang QY, Gu F, Duraiswamy J, Kondreddi RR, Niyomrattanakit P, Lakshminarayana SB, Goh A, Xu HY, Liu W, Liu B, Lim JY, Ng CY, Qing M, Lim CC, Yip A, Wang G, Chan WL, Tan HP, Lin K, Zhang B, Zou G, Bernard KA, Garrett C, Beltz K, Dong M, Weaver M, He H, Pichota A, Dartois V, Keller TH, Shi PY.

Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20435-9. doi: 10.1073/pnas.0907010106. Epub 2009 Nov 16.

18.

Peptide deformylase inhibitors of Mycobacterium tuberculosis: synthesis, structural investigations, and biological results.

Pichota A, Duraiswamy J, Yin Z, Keller TH, Alam J, Liung S, Lee G, Ding M, Wang G, Chan WL, Schreiber M, Ma I, Beer D, Ngew X, Mukherjee K, Nanjundappa M, Teo JW, Thayalan P, Yap A, Dick T, Meng W, Xu M, Koehn J, Pan SH, Clark K, Xie X, Shoen C, Cynamon M.

Bioorg Med Chem Lett. 2008 Dec 15;18(24):6568-72. doi: 10.1016/j.bmcl.2008.10.040. Epub 2008 Oct 14.

PMID:
19008098
19.

Peptide deformylase inhibitors as potent antimycobacterial agents.

Teo JW, Thayalan P, Beer D, Yap AS, Nanjundappa M, Ngew X, Duraiswamy J, Liung S, Dartois V, Schreiber M, Hasan S, Cynamon M, Ryder NS, Yang X, Weidmann B, Bracken K, Dick T, Mukherjee K.

Antimicrob Agents Chemother. 2006 Nov;50(11):3665-73. Epub 2006 Sep 11.

20.

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.

Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry EJ, Coovadia HM, Goulder PJ, Klenerman P, Ahmed R, Freeman GJ, Walker BD.

Nature. 2006 Sep 21;443(7109):350-4. Epub 2006 Aug 20.

PMID:
16921384
21.

Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients.

Gandhi MK, Lambley E, Duraiswamy J, Dua U, Smith C, Elliott S, Gill D, Marlton P, Seymour J, Khanna R.

Blood. 2006 Oct 1;108(7):2280-9. Epub 2006 Jun 6.

PMID:
16757686
22.

Induction of therapeutic T-cell responses to subdominant tumor-associated viral oncogene after immunization with replication-incompetent polyepitope adenovirus vaccine.

Duraiswamy J, Bharadwaj M, Tellam J, Connolly G, Cooper L, Moss D, Thomson S, Yotnda P, Khanna R.

Cancer Res. 2004 Feb 15;64(4):1483-9.

23.

Proteasomal targeting of a viral oncogene abrogates oncogenic phenotype and enhances immunogenicity.

Tellam J, Connolly G, Webb N, Duraiswamy J, Khanna R.

Blood. 2003 Dec 15;102(13):4535-40. Epub 2003 Aug 14.

PMID:
12920032
24.
25.

Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.

Duraiswamy J, Sherritt M, Thomson S, Tellam J, Cooper L, Connolly G, Bharadwaj M, Khanna R.

Blood. 2003 Apr 15;101(8):3150-6. Epub 2002 Dec 5.

PMID:
12468425
26.

Immunotherapeutic strategies for EBV-associated malignancies.

Khanna R, Tellam J, Duraiswamy J, Cooper L.

Trends Mol Med. 2001 Jun;7(6):270-6. Review.

PMID:
11378517

Supplemental Content

Loading ...
Support Center